LONDON (Reuters) -Nicotine alternatives in vapes, like 6-methyl nicotine, may be more potent and addictive. However, scientific data on this remains incomplete, as per the FDA and independent researchers.
Synthetic substances, similar in structure to nicotine, evade U.S. tobacco and vaping regulations. These regulations target traditional nicotine, a highly addictive substance.
Manufacturers can sell vapes with synthetic nicotine analogues, like 6-methyl nicotine, in the United States without FDA authorization. This process can be costly and time-consuming.
Big tobacco firms, such as Altria Group and British American Tobacco, suffered significant U.S. sales losses. This is due to the influx of disposable vapes containing traditional nicotine, sold illegally without FDA authorization.
Altria, the maker of Marlboro cigarettes in the United States, highlighted the emerging use of 6-methyl nicotine in vapes and other smoking alternatives in a May 9 letter to the FDA, according to a copy of the correspondence posted on its website.
“The introduction and growth of chemicals intended to imitate the effects of nicotine, if left unchecked, could present unknown risks to U.S. consumers and undermine FDA’s authority,” the letter said.
Additionally, the FDA Vape Findings underscore the importance of transparency and accurate labeling in the vaping industry.
In conclusion, the FDA Vape Findings signal a critical need for action. Regulatory measures must be implemented to address the potential risks posed by these substances.
Additionally, further research is essential to understand the long-term health effects of vaping and mitigate any adverse impacts on public health.
read more
image source
